Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 8/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.39 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5482661 | 0.90 | CXCR3 (0.53) | CXCR3PRMT5TLR8NOD1CXCR4 | |
| SCHEMBL5463737 | 0.83 | PRMT5 (0.47) | CXCR3PRMT5TLR8NOD1CDK1 | |
| SCHEMBL5473914 | 0.83 | PRMT5 (0.49) | CXCR3PRMT5TLR8NOD1CXCR4 | |
| SCHEMBL14373235 | 0.78 | PRMT5 (0.43) | CXCR3PRMT5TLR8NOD1CASP7 | |
| SCHEMBL5468452 | 0.78 | TLR8 (0.45) | CXCR3TLR8CXCR4 | |
| SCHEMBL14470744 | 0.75 | CXCR3 (0.41) | CXCR3TLR8CXCR4 | |
| SCHEMBL14373381 | 0.73 | CXCR3 (0.84) | CXCR3 | |
| SCHEMBL5453935 | 0.72 | TLR8 (0.66) | PRMT5TLR8NOD1CXCR4 | |
| SCHEMBL5453372 | 0.71 | TLR8 (0.41) | CXCR3TLR8NOD1CDK4 | |
| SCHEMBL5480685 | 0.70 | TLR8 (0.48) | CXCR3PRMT5TLR8CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1983992-A2 | 2-IMINO-BENZIMIDAZOLES | Abbott Laboratories (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20070232673-A1 | 2-Imino-benzimidazoles | ABBOTT LABORATORIES | 2007-10-04 | — | — | US | disclosed |
| US-20070232673-A1 | 2-Imino-benzimidazoles | ABBOTT LABORATORIES | 2007-10-04 | — | — | US | disclosed |
| US-20070232673-A1 | 2-Imino-benzimidazoles | ABBOTT LABORATORIES | 2007-10-04 | — | — | US | disclosed |
| WO-2007084728-A2 | 2-IMINO-BENZIMIDAZOLES | ABBOTT LABORATORIES (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007084728-A2 | 2-IMINO-BENZIMIDAZOLES | ABBOTT LABORATORIES (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232673-A1 | 2-Imino-benzimidazoles | CYP2C19, UGT2B7, UGT2B17 | CXCR3 4743/4885PRMT5 2145/4885TLR8 3837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.